⌘K
Loading ticker…
As of 2026-08-24, Rallybio Corporation Common Stock (RLYB) has a 3-month relative strength percentile of 59 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 88. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 2.7%, relative volume 0.31×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
RLYB is in a stage 2 uptrend, week 12. Currently in a 5-day base; basing ADR 2.5% (broad 3.2%). VCP detected: no. RS line below base-start high. Distance from 50d / 200d: 3.7% / 64.1%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
RLYB appears in 1 ETF as of Apr 2026: DFAS at 0.00% weight, $60K notional.
Held by 3 ETFs · $1M across latest filings · largest weight 0.00% (DFAS).
Top 1 by value, from SEC N-PORT-P filings dated Apr 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| DFASDimensional U.S. Small Cap ETF | 0.00% | $60K | new |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RLYB Jan avg: -13.68% median: -8.42% win: 25% σ: 21.03% n: 4 2022-04-12 → 2026-07-31 | RLYB Feb avg: 29.10% median: 30.09% win: 75% σ: 38.53% n: 4 2022-04-12 → 2026-07-31 | RLYB Mar avg: -9.57% median: -14.91% win: 25% σ: 20.43% n: 4 2022-04-12 → 2026-07-31 | RLYB Apr avg: -6.27% median: 0.11% win: 60% σ: 27.03% n: 5 2022-04-12 → 2026-07-31 | RLYB May avg: 22.79% median: 32.84% win: 60% σ: 30.51% n: 5 2022-04-12 → 2026-07-31 | RLYB Jun avg: -13.03% median: -19.76% win: 40% σ: 23.24% n: 5 2022-04-12 → 2026-07-31 | RLYB Jul avg: 14.02% median: 5.65% win: 80% σ: 16.05% n: 5 2022-04-12 → 2026-07-31 | RLYB Aug avg: 1.38% median: 2.18% win: 50% σ: 18.16% n: 4 2022-04-12 → 2026-07-31 (current) | RLYB Sep avg: -2.74% median: -2.63% win: 50% σ: 27.83% n: 4 2022-04-12 → 2026-07-31 | RLYB Oct avg: 4.62% median: 6.33% win: 50% σ: 33.65% n: 4 2022-04-12 → 2026-07-31 | RLYB Nov avg: -21.83% median: -23.19% win: 25% σ: 30.96% n: 4 2022-04-12 → 2026-07-31 | RLYB Dec avg: 6.65% median: 9.72% win: 75% σ: 18.29% n: 4 2022-04-12 → 2026-07-31 |